Virological features associated with the development of broadly neutralizing antibodies to HIV-1

Trends Microbiol. 2015 Apr;23(4):204-11. doi: 10.1016/j.tim.2014.12.007. Epub 2015 Jan 5.

Abstract

The development of a preventative HIV-1 vaccine remains a global public health priority. This will likely require the elicitation of broadly neutralizing antibodies (bNAbs) able to block infection by diverse viral strains from across the world. Understanding the pathway to neutralization breadth in HIV-1 infected humans will provide insights into how bNAb lineages arise, a process that probably involves a combination of host and viral factors. Here, we focus on the role of viral characteristics and evolution in shaping bNAbs during HIV-1 infection, and describe how these findings may be translated into novel vaccine strategies.

Keywords: HIV-1; broadly neutralizing antibodies; immunotypes; superinfection; vaccine; viral evolution.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / immunology
  • Antibodies, Neutralizing* / biosynthesis
  • Antibodies, Neutralizing* / immunology
  • Antibodies, Neutralizing* / isolation & purification
  • Epitopes / immunology
  • Evolution, Molecular
  • Genetic Variation
  • HIV Antibodies* / biosynthesis
  • HIV Antibodies* / immunology
  • HIV Antibodies* / isolation & purification
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV Infections / virology*
  • HIV-1 / immunology*
  • HIV-1 / physiology
  • Humans
  • South Africa
  • Viral Load
  • env Gene Products, Human Immunodeficiency Virus / genetics
  • env Gene Products, Human Immunodeficiency Virus / immunology

Substances

  • AIDS Vaccines
  • Antibodies, Neutralizing
  • Epitopes
  • HIV Antibodies
  • env Gene Products, Human Immunodeficiency Virus